Document is current

Article History

Accepted: 24 April 2025

First Online: 9 May 2025

Declarations

:

: The study protocol was approved by the Ethics Committee of Tokyo Medical University (study approval no.: T2022-0053).

: Before starting the survey, potential participants were provided with a detailed overview of the study through an online document, which included its objectives, methodology, potential benefits, and risks. It was also announced to the participants that by beginning to answer the survey, they were considered to have provided their consent.

: The authors of this manuscript have read the journal’s policy, and have the following competing interests: Yu Tamada has received personal fees from Otsuka Pharmaceutical Sumitomo Pharma, Eisai, MSD, and Meiji Seika Pharma. Jiro Masuya has received personal fees from Otsuka Pharmaceutical, Eli Lilly, Astellas, and Meiji Yasuda Mental Health Foundation, and grants from Pfizer. Takeshi Inoue has received personal fees from Mochida Pharmaceutical, Takeda Pharmaceutical, Eli Lilly, Janssen Pharmaceutical, MSD, Taisho Toyama Pharmaceutical, Yoshitomiyakuhin, and Daiichi Sankyo; grants from Shionogi, Astellas, Tsumura, and Eisai; and grants and personal fees from Otsuka Pharmaceutical, Sumitomo Pharma, Mitsubishi Tanabe Pharma, Kyowa Pharmaceutical Industry, Pfizer, Novartis Pharma, and Meiji Seika Pharma; and is a member of the advisory boards of Pfizer, Novartis Pharma, and Mitsubishi Tanabe Pharma. All other authors declare that they have no actual or potential conflicts of interest associated with this study. This does not alter our adherence to Current Psychology policies on sharing data and materials.